Corgi All World 2x Daily ETF(WX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

WX Corgi All World 2x Daily ETF

未开盘 08-20 16:00:00 EDT

24.75

-0.26

-1.02%

盘后25.00

+0.26+1.04%

16:10 EDT

最高24.75	最低24.75	成交量97.00
今开25.00	昨收25.00	日振幅0.00%
总市值37.12万	流通市值37.12万	总股本1.50万
成交额2,439	换手率0.65%	流通股本1.50万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"WX","market":"US","secType":"STK","nameCN":"Corgi All World 2x Daily ETF","latestPrice":24.7471,"timestamp":1787256000000,"preClose":25.0033,"halted":0,"volume":97,"hourTrading":{"tag":"盘后","latestPrice":25.0033,"preClose":24.7471,"latestTime":"16:10 EDT","volume":4,"amount":98.9884,"timestamp":1787256604774,"change":0.2562,"changeRate":0.010353,"amplitude":0},"delay":0,"changeRate":-0.010246647442537575,"floatShares":15000,"shares":15000,"eps":0,"marketStatus":"未开盘","change":-0.2562,"latestTime":"08-20 16:00:00 EDT","open":25.0033,"high":24.7471,"low":24.7471,"amount":2439,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1787299200000},"marketStatusCode":0,"adr":0,"exchange":"CBOE","adjPreClose":25.0033,"nav":25,"aum":375000,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":25.0033,"preClose":24.7471,"latestTime":"16:10 EDT","volume":4,"amount":98.9884,"timestamp":1787256604774,"change":0.2562,"changeRate":0.010353,"amplitude":0},"volumeRatio":0.241294},"requestUrl":"/m/hq/s/WX","defaultTab":"news","newsList":[{"id":"2660419923","title":"CXO概念有支撑 凯莱英（06821）涨2.27% 金斯瑞生物科技（01548）涨2.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660419923","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660419923?lang=zh_cn&edition=full","pubTime":"2026-08-19 10:53","pubTimestamp":1787108028,"startTime":"0","endTime":"0","summary":"金吾财讯 | CCXO概念有支撑，凯莱英 涨2.27%、金斯瑞生物科技涨2.41%、百济神州涨0.63%、方达控股涨0.79%、药明生物涨0.04%爱建证券表示，2026年初以来医药板块的持续回调与行业基本面、产业趋势发生背离，近期众多上市公司推出现金回购和增持方案，反映出对产业未来发展的充足信心，CXO、创新药及相关产业链已率先发力反弹，医药板块中长期布局良机已至。同时，该机构看好高景气CXO、器械出海、脑机接口、AI+医疗等投资机会。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/ODBhOTU0MzI3NjMwOTM5MjE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ODBhOTU0MzI3NjMwOTM5MjE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988641","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306685.HKD","LU0052750758.USD","HK0000320223.HKD","LU2328871848.SGD","LU0417516738.SGD","BK1589","LU0819121731.USD","LU0348825331.USD","LU1242518931.SGD","BK0239","LU0181495838.USD","LU0359201612.USD","01521","LU0456827905.SGD","LU0128526141.USD","LU0359202008.SGD","LU0417516902.SGD","LU3063872942.SGD","LU0516422440.USD","LU0828237510.HKD","BK1576","02269","CXO","LU1688375341.USD","BK1610","SG9999002463.SGD","LU1969619763.USD","WX","LU0572944931.SGD","BK1141","LU1720050803.USD","BK1588","BK1500","LU0039217434.USD","LU0043850808.USD","06821","LU0228659784.USD","LU1719994722.HKD","LU0516423091.SGD","KURE","01548","002821","BK1191","LU0708995583.HKD","LU1770034418.SGD","LU0140636845.USD","LU0320764599.SGD","LU0588546209.SGD","06160","LU0516422366.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660490014","title":"国产创新药迎三重业绩拐点 CXO龙头利润与订单同步创出历史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2660490014","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660490014?lang=zh_cn&edition=full","pubTime":"2026-08-19 07:25","pubTimestamp":1787095509,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["WX","MEDX","IBBQ","LNGR","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660464424","title":"CXO开启主升浪，药明系、金斯瑞、康龙等集体突破！华宝基金港股通医疗ETF创5个月收盘新高，医疗ETF8天7阳","url":"https://stock-news.laohu8.com/highlight/detail?id=2660464424","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660464424?lang=zh_cn&edition=full","pubTime":"2026-08-18 19:45","pubTimestamp":1787053500,"startTime":"0","endTime":"0","summary":"8月18日，CXO强者恒强，继续领涨医疗板块！场内高CXO含量ETF继续上行，港股通医疗ETF华宝标的指数CXO含量全市场第一，场内价格续涨1.25%创5个月收盘新高！全市场规模最大医疗ETF华宝CXO含量超30%，斩获8天7阳。药明康德半年度净利润历史首次突破百亿元大关，并大幅上调全年指引；康龙化成Q2收入和经调利润分别同比增长19.38%和22.3%；昭衍新药上半年归母净利润同比预增884.9%至1377.4%。其中药明系占比超38%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-18/doc-inintxxh8569801.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CXO","WX","159828","FLHK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660138101","title":"CXO再度爆发，药明康德H股叒新高！华宝基金港股通医疗ETF（159137）上探3.5%，标的指数CXO含量全市场第一","url":"https://stock-news.laohu8.com/highlight/detail?id=2660138101","media":"新浪基金","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660138101?lang=zh_cn&edition=full","pubTime":"2026-08-17 11:19","pubTimestamp":1786936740,"startTime":"0","endTime":"0","summary":"8月17日，港股通医疗板块强势反弹，CXO再度领涨，药明康德港股再创历史新高！场内热门ETF方面，可T+0交易的港股通医疗ETF华宝盘中上探3.5%收复5日线！数据显示，其标的指数CXO含量达52.5%，在全市场可投资指数中为最高，其中药明系权重占比超38%，同样高居首位。最新CXO含量达32.82%，其中药明康德（A股）占比13.42%。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-17/doc-ininqtns0348637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0611395673.USD","LU1808992512.USD","FLHK","LU0327786744.USD","LU1719994722.HKD","BK1583","LU2488822045.USD","02359","LU1303224171.USD","159137","LU0469268626.HKD","LU1934453819.USD","LU0708995583.HKD","WX","LU1046422090.SGD","LU2328871848.SGD","IE00BPRC5H50.USD","603259","BK0216","LU1979443071.USD","LU2495084118.USD","LU0572944931.SGD","LU1997244956.HKD","LU1997245177.USD","BK1576","LU2242644610.SGD","BK1141","LU0320764599.SGD","LU2125910500.SGD","LU0348767384.USD","LU1770034418.SGD","IE00B543WZ88.USD","LU0456842615.SGD","LU1997245094.SGD","LU0348766576.USD","LU1969619763.USD","159828","LU1251922891.USD","LU0052750758.USD","LU2045819591.USD","CXO","IE00B5MMRT66.SGD","LU0700851271.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660810134","title":"强业绩引爆CXO行情，哪个可投资指数CXO含量最高？","url":"https://stock-news.laohu8.com/highlight/detail?id=2660810134","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660810134?lang=zh_cn&edition=full","pubTime":"2026-08-17 11:03","pubTimestamp":1786935780,"startTime":"0","endTime":"0","summary":"🔥药明康德交出史上最强中报🚀CXO行业景气上行持续验证一键投资CXO，关注T+0利器👇🏻🔥港股通医疗ETF华宝#159137❤️标的指数CXO含量52.5%，全市场第一❗💙其中药明系权重占比超38%🐲投龙头·选华宝⚠️市场有风险，投资须谨慎","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-17/doc-ininqtnu9181150.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CXO","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659612294","title":"订单饱满结构升级 CXO企业半年度业绩释放回暖信号","url":"https://stock-news.laohu8.com/highlight/detail?id=2659612294","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659612294?lang=zh_cn&edition=full","pubTime":"2026-08-15 07:30","pubTimestamp":1786750211,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CXO","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659187744","title":"CXO强者恒强！药明康德AH股齐升，皓元医药涨超8%！华宝基金医疗ETF（512170）涨超2%冲击五连阳","url":"https://stock-news.laohu8.com/highlight/detail?id=2659187744","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659187744?lang=zh_cn&edition=full","pubTime":"2026-08-13 11:25","pubTimestamp":1786591500,"startTime":"0","endTime":"0","summary":"8月13日，AH医疗板块迅速反弹。CXO强者恒强，药明康德AH股双双涨逾1%，康龙化成AH股齐升逾4%，A股皓元医药涨超7%。场内高CXO含量ETF同步走走强，CXO含量超50%的港股通医疗ETF华宝涨逾1%。全市场规模最大医疗ETF华宝CXO含量超30%，盘中涨超2%冲击五连阳，成交超4.5亿元。紧跟医疗反攻行情，关注两大“利器”：港股通医疗ETF华宝：最新CXO含量达51.88%，其中药明系权重占比超38%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-13/doc-ininctaw3414344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159828","603259","LU2488822045.USD","BK1583","LU1808992512.USD","LU2045819591.USD","LU0052750758.USD","LU1046422090.SGD","LU1997244956.HKD","LU1934453819.USD","LU0708995583.HKD","LU2495084118.USD","LU1770034418.SGD","LU0320764599.SGD","LU1997245177.USD","LU2125910500.SGD","LU0456842615.SGD","IE00B543WZ88.USD","LU2328871848.SGD","BK1576","LU1969619763.USD","IE00BPRC5H50.USD","LU0700851271.USD","512170","BK0216","688131","WX","LU1303224171.USD","LU0611395673.USD","LU1979443071.USD","BK1141","02359","IE00B5MMRT66.SGD","LU0348766576.USD","LU1997245094.SGD","LU2242644610.SGD","LU0348767384.USD","LU1719994722.HKD","LU1251922891.USD","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659182702","title":"美银证券：中国CXO行业受惠生物科技融资强劲 上调药明康德(02359)等目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=2659182702","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659182702?lang=zh_cn&edition=full","pubTime":"2026-08-13 10:20","pubTimestamp":1786587659,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，美银证券发布研报称，受惠上半年全球及中国生物科技一级市场融资表现强劲，加上创新药对外授权交易持续活跃，预期研发活动将进一步加快，中国CRO/CDMO企业可望受惠。该行上调药明康德H股目标价由204.3港元至242港元，药明康德A股目标价由177.8元人民币至210.5元人民币，维持“买入”评级，因其增长能见度清晰。该行并上调药明康德2029至2035年收入估算介乎3%至7%，经调整纯利预测亦上调介乎3%至7%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479310.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PSCH","LFSC","PSIL","XBIX","MEDI","SMCO","IDNA","IBRN","APXH","02359","WX","603259","SURI","BMED","161027","CXO","BBC","FHLC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658288069","title":"医药调研热度超越半导体！创新药回调，华宝基金港股通创新药ETF失守半年线！CXO韧性十足，药明系逆市飘红","url":"https://stock-news.laohu8.com/highlight/detail?id=2658288069","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658288069?lang=zh_cn&edition=full","pubTime":"2026-08-12 11:02","pubTimestamp":1786503720,"startTime":"0","endTime":"0","summary":"业绩兑现叠加AI制药概念加持，CXO韧性十足，药明生物、药明康德、药明合联逆市飘红，金斯瑞生物科技续涨逾1%。港股通创新药龙头股批量飘绿，百济神州跌2%止步6连阳，翰森制药跌逾3%；再鼎医药延续涨势，股价创年内新高。100%创新药研发标的——港股通创新药ETF华宝冲高回落，现跌1%再失半年线。8月以来，创新药及产业链利好密集，“吃药”行情持续上演。同期医药生物行业的市场关注度大幅攀升。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-12/doc-inimzqcp6895872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["SMHU","SSG","VGT","MQQQ","CHPS","CXO","BK4588","FLHK","SOXX","XSD","BK1161","EIS","159992","159938","BK4535","CWC","WX","MEDX","SOXY","09939","BK1515","TECY","IBBQ","FWD","SMH","NBDS","USD","SMHX","CHPY","159582","SOXQ","LNGR","PSI","FTXL","SOXS","159316","TEKX","06978","BK4585","BK1574","SOXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657698357","title":"港股CXO近日股价集体走高，盈警之后的泰德医药(03880)将逆市下跌还是超跌反弹？","url":"https://stock-news.laohu8.com/highlight/detail?id=2657698357","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657698357?lang=zh_cn&edition=full","pubTime":"2026-08-07 10:22","pubTimestamp":1786069332,"startTime":"0","endTime":"0","summary":"7月31日盘后，泰德医药发布了其26H1财年盈警公告。目前泰德医药尚未迎来连续数个交易日的低点逐步抬高以彻底终结下跌趋势，关键的量能均线也尚未出现明显转折。近日，港股医药概念股集体走高，CXO、创新药板块多点爆发，带动恒生医疗保健指数强势反弹。以8月4日行情为例，港股CXO板块出现一波个股集体走高，其中药明康德股价大涨11.17%，康龙化成和泰格医药均涨超5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477144.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4588","CXO","WX","NIFE","KCAI","03880","BK4585","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657657002","title":"【券商聚焦】中信建投：CXO 行业复苏明确，海内外医药投融资同步回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657002","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657657002?lang=zh_cn&edition=full","pubTime":"2026-08-06 09:04","pubTimestamp":1785978243,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投表示，国内CXO行业经历22-24年的调整阶段后，受益海外投融资率先回暖，24年国内头部CXO公司海外订单展现复苏态势，随着25年国内创新药资产实现大规模对外授权，带动国内投融资25H2持续复苏，行业内需同样企稳回升。26年至今国内创新药行业的长期结构性机会持续兑现，国内投融资持续改善，新药物形式赛道持续火热并进一步放量，该机构认为26年国","market":"nz","thumbnail":"https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987586","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","BK1161","BK1515","CXO","WX","BK0276","601066","09939","KCE","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657572212","title":"中信建投：CXO板块Beta稳中向好，AI制药大有可为","url":"https://stock-news.laohu8.com/highlight/detail?id=2657572212","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657572212?lang=zh_cn&edition=full","pubTime":"2026-08-06 07:41","pubTimestamp":1785973273,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["QTOC","WX","CHAT","ARTY","AIPO","VTHR","CXO","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657591587","title":"CXO巨头爆量上涨！开盘45分钟成交120亿元，超上日全天！规模最大医疗ETF（512170）创本轮反弹新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2657591587","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657591587?lang=zh_cn&edition=full","pubTime":"2026-08-05 10:35","pubTimestamp":1785897300,"startTime":"0","endTime":"0","summary":"CXO巨头药明康德重磅财报继续发酵！8月5日早盘，药明康德A股爆量上行，盘初一度续涨逾6%，截至10：15涨4.6%，成交超120亿元，超越上日全天，跻身A股成交额前五！全市场规模最大医疗ETF华宝同步上扬，场内价格创本轮反弹新高！数据显示，药明康德为医疗ETF华宝第一大重仓股，最新持仓占比达12.69%。高效参与CXO交易，关注两大“利器”：医疗ETF华宝：全市场规模最大医药医疗类ETF，聚焦医疗器械+医疗服务，兼顾AI医疗概念。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-05/doc-inimfshm5200987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["WX","512170","CXO","159828"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656158919","title":"港股异动 | CRO概念股涨幅居前 近期多家海外MNC与CXO披露中报盈喜并上调全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2656158919","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656158919?lang=zh_cn&edition=full","pubTime":"2026-08-04 11:05","pubTimestamp":1785812703,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，CRO概念股涨幅居前，截至发稿，药明康德涨11.05%，报180.9港元；金斯瑞生物科技涨10.18%，报17.96港元；凯莱英涨7.71%，报117.4港元；药明生物涨3.92%，报40.34港元。消息面上，药明康德公告称，上半年公司实现营业收入288.97亿元，同比增长38.93%；归母净利润110.8亿元，同比增长29.43%。值得注意的是，近期已有多家多家海外MNC与CXO披露中报盈喜并上调全年指引。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475611.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306685.HKD","LU0052750758.USD","BK1521","LU0417516738.SGD","BK1589","LU0348825331.USD","LU0181495838.USD","LU0348766576.USD","LU0327786744.USD","LU0456827905.SGD","LU0516423174.USD","LU0359202008.SGD","LU0417516902.SGD","LU3063872942.SGD","LU0516422440.USD","BK1583","LU1242518857.USD","BK1576","02269","02359","CXO","LU1688375341.USD","LU0979878070.USD","LU0456846285.SGD","BK1610","LU0823426480.USD","SG9999002463.SGD","WX","LU1794554557.SGD","BK4588","HK0000306701.USD","BK4585","VXUS","BK1141","LU1720050803.USD","LU0039217434.USD","LU0043850808.USD","LU1046422090.SGD","06821","KCAI","KURE","LU0856984785.SGD","01548","LU0348767384.USD","BK1191","LU0708995583.HKD","LU0516422952.EUR","LU0140636845.USD","LU1242518931.SGD","LU0588546209.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654095486","title":"医药外包概念全线扬升 昭衍新药(06127)涨7.93% 机构指CXO景气进入中报业绩兑现期","url":"https://stock-news.laohu8.com/highlight/detail?id=2654095486","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654095486?lang=zh_cn&edition=full","pubTime":"2026-07-27 10:17","pubTimestamp":1785118673,"startTime":"0","endTime":"0","summary":"消息面上，开源证券新近研究指出，7月以来，康龙化成、昭衍新药、美迪西和药康生物先后发布2026年H1业绩预增公告，从早研到临床前研究，CXO景气周期已逐步进入利润表兑现期。根据医药魔方，2026H1全球创新药一级市场共发生505起融资事件，同比增长6.1%，融资金额达到267.5亿美元，同比增长58.5%。2026H1中国相关交易数量及金额涨势迅猛，总金额达997亿美元。从6月初至今，CXO板块在业绩和订单的支撑下，率先于创新药反弹。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986787","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348766576.USD","WX","LU1880383366.USD","LU0307460666.USD","LU1046422090.SGD","HK0000306685.HKD","LU0043850808.USD","03347","LU0516423174.USD","LU0856984785.SGD","LU0588546209.SGD","BK1141","LU0417516738.SGD","01548","BK1589","LU2039709279.SGD","BK0216","LU0348767384.USD","LU1242518931.SGD","LU0516422440.USD","02359","06821","03759","BK1161","09939","LU0140636845.USD","KURE","01873","LU0359201612.USD","BK1583","BK1610","LU0348735423.USD","LU2125910500.SGD","603127","CXO","06127","BK1191","BK1574","LU0327786744.USD","02269","LU0039217434.USD","LU0823426308.USD","LU0516422952.EUR","LU0823426480.USD","159938","LU3063872942.SGD","SG9999002562.SGD","LU2242644610.SGD","LU1242518857.USD","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653270629","title":"中信建投：CXO板块Beta稳中向好 个股订单加速兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2653270629","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653270629?lang=zh_cn&edition=full","pubTime":"2026-07-24 13:46","pubTimestamp":1784871966,"startTime":"0","endTime":"0","summary":"26年至今国内创新药行业的长期结构性机会持续兑现，国内投融资持续改善，新药物形式赛道持续火热并进一步放量，该行认为26年国内CRO/CDMO行业的新签订单及业绩会加速增长，带动CXO产业链进入新一轮发展阶段。随着资金由融资端向CXO逐级传导，叠加板块估值仍处历史较低水平，行业业绩与估值有望持续修复。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CXO","BK0276","601066","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653772632","title":"中信建投：2026年国内CRO/CDMO行业的新签订单及业绩会加速增长，带动CXO产业链进入新一轮发展阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2653772632","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653772632?lang=zh_cn&edition=full","pubTime":"2026-07-24 08:20","pubTimestamp":1784852419,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","CDMO","CXO","WX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.wuxiapptec.com","stockEarnings":[{"period":"1week","weight":-0.032},{"period":"1month","weight":0.0386},{"period":"3month","weight":0.0011},{"period":"ytd","weight":0.0011}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":0.0191},{"period":"3month","weight":0.0227},{"period":"6month","weight":0.1061},{"period":"1year","weight":0.1951},{"period":"ytd","weight":0.1183}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"药明康德在开曼群岛注册成立于2004年6月3日，没有显著的资产或它自己的业务。几乎所有在中国开展的业务都是通过其主要运营子公司，WXAT，一家于2000年12月成立的药明康德新药开发有限公司。公司的核心业务是提供发现化学服务在药物发现过程的开始合成的小分子。该公司是一家全球领先的制药、生物技术以及医疗器械研发外包服务公司。公司的核心业务是在药物发展过程的开始阶段为合成小分子提供发现化学服务。公司主要在中国和美国经营业务。公司在研发过程中提供一系列全方位的实验室及制造服务给客户，这些客户包括许多世界一流的制药、生物技术和医疗器械公司。公司的服务旨在帮助全球客户缩短时间，并通过提供具有成本效益和高效率的外包解决方案，降低药品和医疗器械的研发成本。","exchange":"CBOE","name":"Corgi All World 2x Daily ETF","nameEN":"Corgi All World 2x Daily ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Corgi All World 2x Daily ETF(WX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Corgi All World 2x Daily ETF(WX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Corgi All World 2x Daily ETF,WX,Corgi All World 2x Daily ETF股票,Corgi All World 2x Daily ETF股票老虎,Corgi All World 2x Daily ETF股票老虎国际,Corgi All World 2x Daily ETF行情,Corgi All World 2x Daily ETF股票行情,Corgi All World 2x Daily ETF股价,Corgi All World 2x Daily ETF股市,Corgi All World 2x Daily ETF股票价格,Corgi All World 2x Daily ETF股票交易,Corgi All World 2x Daily ETF股票购买,Corgi All World 2x Daily ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Corgi All World 2x Daily ETF(WX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Corgi All World 2x Daily ETF(WX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}